-

Hub Group (HUBG) Shares Crater Amid Admitted Improper Accounting – Hagens Berman

SAN FRANCISCO--(BUSINESS WIRE)--Hub Group, Inc. (NASDAQ: HUBG) shares fell over 27% during trading on Feb. 6, 2026, after the company filed a report with the SEC that its quarterly reports going back to March 31, 2025, “should no longer be relied upon.”

"[The company’s quarterly reports] should no longer be relied upon.”

Share

These events prompted Hagens Berman, a national shareholder rights law firm, to investigate whether Hub Group may have intentionally misled investors about whether its financial statements are consistent with relevant accounting rules. The firm urges Hub Group investors who suffered significant losses to contact the firm now.

Key information:

About the Hub Group, Inc. (HUBG) Investigation:

Hub Group previously assured investors that its financial statements were prepared in conformity with generally accepted accounting principles, that the company fairly presented its financial condition, and that its disclosure controls and procedures were sufficient.

However, on Feb. 5, 2026, Hub Group filed a report with the SEC warning investors not to rely on several quarterly reports because the company understated “purchased transportation costs and accounts payable in the first nine months of 2025.” The quarterly reports in question include the periods ended March 31, June 30 and Sept. 30, 2025.

Hub Group also revealed that it “expects to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for the year ended December 31, 2025[,]” and that it “is continuing to assess the potential impact to its consolidated financial statements for the years ended December 31, 2024 and 2023.”

In response, Hub Group shares fell as much as $14.16 (-27%), wiping out over $800 million of market capitalization in a single day.

“We’re investigating whether Hub Group may have intentionally understated its expenses and if other fiscal years may also be impacted,” said Reed Kathrein, Hagens Berman partner leading the firm’s investigation.

If you suffered substantial losses, contact Hagens Berman at www.hbsslaw.com/investor-fraud/hubg

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights law firm specializing in complex litigation and corporate accountability. The firm represents investors, whistleblowers, workers, and others harmed by corporate wrongdoing. Hagens Berman has secured $2.9 billion in this area of law. More at hbsslaw.com and @ClassActionLaw.

Contacts

Reed Kathrein, 844-916-0895

Hagens Berman

NASDAQ:HUBG

Release Versions

Contacts

Reed Kathrein, 844-916-0895

More News From Hagens Berman

Kyndryl Holdings (KD) Shares Crater Amid Late Filing, Abrupt CFO and GC Departures, SEC Investigation – Hagens Berman

SAN FRANCISCO--(BUSINESS WIRE)--Kyndryl Holdings, Inc. (NYSE: KD) shares fell nearly 57% on Feb. 9, 2026, after the company announced it would not timely file its quarterly report for the quarter ended Dec. 31, 2025, and that its CFO, David Wyshner, and General Counsel, Edward Sebold, departed the company. These events prompted Hagens Berman, a national shareholder rights law firm, to investigate whether the company may have misled investors about assurances that its financial statements were p...

Hagens Berman: Lawsuit Details Excessive Harassment and Employment Retaliation at Snohomish County Juvenile Detention Center

SEATTLE--(BUSINESS WIRE)--Snohomish Co. has been sued for retaliation after a former officer reported harassment at Denney Juvenile Justice Center, according to Hagens Berman....

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA had warned the company “on several occasions” not to submit its application for relacorilant, its proposed treatment for hypercortisolism. The report sent Corcept shares down, wiping ou...
Back to Newsroom